n
a
v
Portfolio
Genetics
AmplideX® Fragile X Dx & Carrier Screen Kit
AmplideX® mPCR FMR1 Kit
AmplideX® PCR/CE FMR1 Kit
AmplideX® FMR1 Controls
Xpansion Interpreter®
AmplideX® PCR/CE
SMN1/2
Plus Kit
AmplideX® PCR/CE
CFTR
Kit
AmplideX® PCR/CE C9orf72 Kit
AmplideX® PCR/CE
DMPK
Kit
AmplideX® PCR/CE
HTT
Kit
AmplideX® TRIO
Oncology
QuantideX® qPCR BCR-ABL IS Kit
QuantideX® qPCR BCR-ABL minor Kit
MolecularDx Controls
Catalog of Armored Products
SARS CoV-2 Controls
Made-To-Order Armored and Nucleic Acid
Molecular Assay Reagents
Custom & Companion Diagnostics
Partnered R&D
CAP-Accredited CLIA Lab
CTA Testing Site
Validated Platforms & Assays
Companion Diagnostics
Enabling Technologies
Assay Chemistries
Bioinformatics
Product Development Process
Resources
Publications
Articles
Whitepapers
Posters
Disease Information
Fragile X
Leukemia
Dementia
Other Resources
Videos
Carrier Screening Guide
Safety Data Sheets
Sales Contacts
Our Culture
Employee Spotlights
Culture & Heritage
Sales Contacts
About
Leadership Team
Culture and Heritage
Press Releases
Upcoming Events
Business Development
Contact
Careers
Search
News
Home
News
Press Releases
Year
Select Year
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
March 24, 2015
Asuragen to present innovations in fragile X testing at upcoming American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
Share
January 12, 2015
Asuragen to join leading UK cancer research consortium to develop miRNA based sequencing tests for early detection and screening of cancer
Share
November 11, 2014
Asuragen Launches the QuantideX® qPCR DNA QC Assay to Improve the Accuracy of Next-Generation Sequencing
Share
October 5, 2014
Asuragen to present at upcoming Association for Molecular Pathology Annual Meeting in National Harbor, MD
Share
September 17, 2014
Asuragen’s Xpansion Interpreter® Test Study of 1,040 Transmissions of Fragile X Alleles Reveals Personalized Risks for Expansion from Parent to Child
Share
September 4, 2014
Asuragen and Labceutics Report Results from Pan European Quality Assurance-Modeled Study on Standardization of BCR-ABL1 Monitoring for CML Patients
Share
August 5, 2014
Asuragen Names Matthew McManus, M.D., Ph.D., President and CEO
Share
July 10, 2014
Asuragen Receives New York State License for Molecular Genetic and Oncology Clinical Laboratory Testing
Share
November 11, 2013
Asuragen to present at upcoming Association for Molecular Pathology Annual Meeting on Genomic Medicine
Share
October 8, 2013
Asuragen Receives Notice of Patent Allowance for Broad Diagnostic Application of miR-21 in Cancer
Share
Prev
1
…
3
4
5
6
7
8
Next
About
About
Leadership Team
Culture and Heritage
Press Releases
Upcoming Events
Business Development
Back To
Top